Topic

Zolgensma (onasemnogene abeparvovec-xioi)

A collection of 21 issues

How to Get Zolgensma (onasemnogene abeparvovec-xioi) Covered by Humana in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zolgensma Covered by Humana in New Jersey Zolgensma (onasemnogene abeparvovec-xioi) requires prior authorization from Humana Medicare Advantage plans in New Jersey as a high-cost specialty gene therapy (HCPCS J3399). Coverage requires genetic confirmation of SMA with SMN1 mutation, age under 2 years, negative AAV9 antibody titers, and
6 min read

How to Get Zolgensma Covered by UnitedHealthcare in North Carolina: Complete Prior Authorization & Appeals Guide

Answer Box: Getting Zolgensma Covered by UnitedHealthcare in North Carolina UnitedHealthcare requires prior authorization through OptumRx for Zolgensma (onasemnogene abeparvovec-xioi) with strict clinical criteria: genetic confirmation of bi-allelic SMN1 mutations, age under 2 years, anti-AAV9 antibody titer ≤1:50, and documented steroid protocol. If denied, North Carolina residents can appeal
7 min read

How to Get Zolgensma (onasemnogene abeparvovec-xioi) Covered by Humana in Michigan: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zolgensma Covered by Humana in Michigan Zolgensma requires prior authorization from all Humana plans in Michigan. For Medicare Advantage members, submit via Humana's medical benefit PA process using HCPCS J3399. Commercial members use pharmacy benefit channels. Key requirements: genetic confirmation of SMA, age/weight within
6 min read

Work With Your Doctor to Get Zolgensma Covered by UnitedHealthcare in Washington: Prior Authorization, Appeals, and Documentation Guide

Answer Box: Get Zolgensma Covered by UnitedHealthcare in Washington Fastest path: Partner with your pediatric neurologist to submit a complete prior authorization including genetic confirmation of bi-allelic SMN1 mutation, anti-AAV9 antibody titer ≤1:50, and detailed medical necessity letter. UnitedHealthcare requires PA for all Zolgensma cases with 45-day authorization window
7 min read